{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.7","upperLimit":"55.7","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Bone marrow samples were evaluated for MRD remission by a central laboratory using bcr-abl fusion gene reverse transcription polymerase chain reaction (RT-PCR).\n\nAn MRD response was defined as MRD \\< 10\\^-4 measured by PCR. Participants with no post-baseline MRD assessment were considered non-responders.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"All participants who received an infusion of blinatumomab.","reportingStatus":"POSTED","timeFrame":"Approximately 12 weeks","title":"Percentage of Participants With Minimal Residual Disease (MRD) Remission During the First 2 Cycles of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}